Maribavir

Generic Name
Maribavir
Brand Names
Livtencity
Drug Type
Small Molecule
Chemical Formula
C15H19Cl2N3O4
CAS Number
176161-24-3
Unique Ingredient Identifier
PTB4X93HE1
Background

Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation. Most standard CMV therapies, such as ganciclovir or foscarnet, target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to DNA polymerase-based ther...

Indication

Maribavir is indicated for the treatment of post-transplant cytomegalovirus (CMV) infection (following hematopoietic stem cell transplant or solid organ transplant) which is refractory to standard treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet.
...

Associated Conditions
Post-transplant Cytomegalovirus (CMV) Infection
Associated Therapies
-
Clinical Trials
Related News

A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection

Not yet recruiting
Conditions
Cytomegalovirus (CMV)
Interventions
Drug: Maribavir
First Posted Date
2024-08-29
Last Posted Date
2024-08-29
Lead Sponsor
Takeda
Target Recruit Count
250
Registration Number
NCT06577363
Locations
🇯🇵

Takeda selected site, Tokyo, Japan

A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

Recruiting
Conditions
Cytomegalovirus (CMV)
Interventions
Drug: LIVTENCITY
First Posted Date
2024-08-15
Last Posted Date
2024-11-20
Lead Sponsor
Takeda
Target Recruit Count
168
Registration Number
NCT06555432
Locations
🇰🇷

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Phase 3
Not yet recruiting
Conditions
Cytomegalovirus (CMV)
Interventions
Drug: Maribavir
First Posted Date
2024-06-03
Last Posted Date
2024-06-06
Lead Sponsor
Takeda
Target Recruit Count
20
Registration Number
NCT06439342
Locations
🇨🇳

Peking University People's Hospital, Beijing, North China, China

Maribavir Vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Phase 4
Active, not recruiting
Conditions
CMV
Transplant Complication
Interventions
Drug: Valganciclovir
Drug: Maribavir
First Posted Date
2023-09-13
Last Posted Date
2024-10-11
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
70
Registration Number
NCT06034925
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Maribavir Food-Effect Study in Healthy Adults Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Maribavir
First Posted Date
2022-05-19
Last Posted Date
2024-02-16
Lead Sponsor
Takeda
Target Recruit Count
31
Registration Number
NCT05382104
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Phase 3
Active, not recruiting
Conditions
Cytomegalovirus (CMV)
Interventions
Drug: Maribavir
First Posted Date
2022-04-08
Last Posted Date
2024-12-10
Lead Sponsor
Takeda
Target Recruit Count
80
Registration Number
NCT05319353
Locations
🇧🇷

Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

🇧🇷

Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre, Rio Grande Do Sul, Brazil

🇧🇷

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Porto Alegre, Rio Grande Do Sul, Brazil

and more 44 locations

A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection

Phase 3
Completed
Conditions
Cytomegalovirus (CMV)
Interventions
Drug: Maribavir
First Posted Date
2021-11-30
Last Posted Date
2024-07-09
Lead Sponsor
Takeda
Target Recruit Count
41
Registration Number
NCT05137717
Locations
🇯🇵

Ehime University Hospital, Toon, Ehime, Japan

🇯🇵

Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan

🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

and more 17 locations

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

Phase 1
Terminated
Conditions
Healthy Volunteers
Interventions
Drug: Maribavir
First Posted Date
2019-10-18
Last Posted Date
2021-01-19
Lead Sponsor
Shire
Target Recruit Count
20
Registration Number
NCT04131556
Locations
🇺🇸

Clinical Pharmacology of Miami, Llc, Miami, Florida, United States

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

First Posted Date
2016-10-13
Last Posted Date
2021-11-03
Lead Sponsor
Shire
Target Recruit Count
352
Registration Number
NCT02931539
Locations
🇺🇸

University of Maryland, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

and more 129 locations

A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

First Posted Date
2016-10-06
Last Posted Date
2023-03-03
Lead Sponsor
Shire
Target Recruit Count
553
Registration Number
NCT02927067
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

UMass Memorial Medical Center, Worcester, Massachusetts, United States

🇺🇸

Columbia University Medical Center, New York, New York, United States

and more 126 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy